QCI Asset Management Inc. NY Acquires 8,099 Shares of Bristol-Myers Squibb Co (BMY)

QCI Asset Management Inc. NY increased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 239,865 shares of the biopharmaceutical company’s stock after acquiring an additional 8,099 shares during the quarter. Bristol-Myers Squibb comprises 1.7% of QCI Asset Management Inc. NY’s holdings, making the stock its 24th biggest position. QCI Asset Management Inc. NY’s holdings in Bristol-Myers Squibb were worth $15,289,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tradewinds Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares in the last quarter. Atlantic Trust LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $111,000. Blue Chip Partners Inc. raised its stake in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares in the last quarter. BDO Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $123,000. Finally, Acrospire Investment Management LLC raised its stake in shares of Bristol-Myers Squibb by 633.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 1,900 shares in the last quarter. Hedge funds and other institutional investors own 69.67% of the company’s stock.

Several research firms recently commented on BMY. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price objective for the company. in a research note on Thursday, December 28th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Monday, December 11th. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $65.05.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.81 on Friday. The firm has a market cap of $102,801.13, a P/E ratio of 21.22, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 EPS. equities analysts expect that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a $0.40 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is 62.99%.

In other news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/qci-asset-management-inc-ny-acquires-8099-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply